Advertisement
Advertisement
-
Pfizer
TOPIC
 / company

Pfizer

Pfizer
Pfizer
The latest news, analysis and opinion on Pfizer. In-depth analysis, industry insights and expert opinion.
Chairman / President
Albert Bourla
CEO / Managing Director
Albert Bourla
CFO / Finance Director
Dave Denton
Industry
Pharmaceuticals
Website
pfizer.com
Headquarters address
235 East 42nd Street, New York, NY 10017, United States
Stock Code
NYSE:PFE
Year founded
1849
LATEST China Science NEWS

Steve Durst – the US citizen space diplomat who reached out to China

videocam
5
Steve Durst (second right) poses with collaboration partners from mainland China, Hong Kong and Thailand at the second International Deep Space Exploration Conference (Tiandu Forum) in Anhui, in September 2024. Photo: Handout

China’s first man in space Yang Liwei officially retires from active duty

Yang Liwei emerges from the Shenzhou-5 re-entry capsule in October 2003. Photo: Handout

China’s green energy leader Inner Mongolia is working on ‘flexible’ power plants

videocam
Inner Mongolia provides 57 per cent of the country’s exploitable wind power. Photo: Handout

Top neuroscientist Arthur Konnerth leaves Germany for full-time role in China

videocam
75
Arthur Konnerth is a leading figure in neuroscience whose work has helped transform the understanding of how the brain processes information. Photo: Handout

Japanese paper-cutting art inspires China science team’s flexible brain implants

videocam
11
Chinese scientists said the design of their stretchable microelectrodes was inspired by the Japanese art of paper cutting. Photo: ScienceNet
MORE China Science NEWS
US President Donald Trump at the TrumpRx website launch. Photo: EPA
Medicine

‘Save a fortune’: Trump unveils TrumpRx discount drug site

New platform connects American patients directly to drug makers with promised price cuts on popular medications like Ozempic.

Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Advertisement
Advertisement
Advertisement
Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

A number of Chinese biotech firms have clinched licensing deals with multinational companies this year. Photo: Shutterstock
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
Science

Have Chinese chemists cracked the code for cheaper medicine production?

The research team’s straightforward alternative to expensive, complex and dangerous production method hailed as ‘Nobel Prize level’.

videocam
18
A study by researchers in China proposes an alternative to how medicinal compounds are traditionally made, which could make them cheaper to produce. Photo: AFP
US-China relations

Xi-Trump summit opens window of opportunity for US firms at China import expo

More US companies are expected at this year’s China International Import Expo, hoping to secure deals in wake of bilateral summit.

videocam
Preparations are nearly complete for this year’s China International Import Expo in Shanghai. Photo: Xinhua
Hong Kong economy

Letters | How Hong Kong can help Chinese drug makers go global

Readers discuss opportunities from medical innovation, tech standards in Hong Kong, and how to stop people treating corals like inanimate objects.

Donald Trump

Trump says Pfizer will cut drug prices for tariff relief

The White House is also planning a direct-to-consumer website called TrumpRx for Americans to buy medication.

Singapore

Singapore’s drug makers may be shielded from US tariffs: Deputy PM Gan

The city state may pursue a ceiling on tariff rates similar to deals that Washington has with other countries, Deputy PM Gan Kim Yong adds.

Singapore’s Deputy Prime Minister Gan Kim Yong addresses the US tariffs during a task force meeting in the city state in April. Photo: Reuters
Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

The Pfizer deal is not good news for Chinese firms developing weight-loss drugs with the aim of reducing injections, an analyst says. Photo: Shutterstock
Biomedicine: Companies

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.

Made in China 2025

China vows stronger biotech support as deals with global drug makers surge

Chinese developers signed one-third of all agreements with global drug firms in the first half of 2025.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.

Pfizer agreed to buy a 1.3 per cent equity stake in 3SBio for HK$785 million. Photo: Shutterstock
European Union

EU chief Ursula von der Leyen easily survives parliament no-confidence vote

EU lawmakers dismissed allegations against Ursula von der Leyen regarding private text messaging with Pfizer’s CEO, misuse of funds, and election interference.

Singapore

Singapore prioritising pharmaceutical supply chains in US tariff talks

Pharmaceutical supply chains account for more than 10 per cent of Singapore’s exports to the US.

CSPC Pharmaceutical

Chinese biotech’s mega drug-licensing deals with multinationals surge

Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.

Good mid-stage drug candidates from China at prices far below those in the US market are driving an increase in licensing deals, analysts say. Photo: Shutterstock
Biomedicine: Companies

Chinese biotech firm secures Pfizer deal despite trade tensions

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s 3SBio.

videocam
3SBio was established in 1993 with an initial focus on interferons, a type of protein that helps the immune system. Photo: Handout
European Union

EU’s von der Leyen loses court case over secret Pfizer texts

Wednesday’s ruling is likely to affect how the EU’s executive arm treats text messages in the future.

Biomedicine: Companies

Hong Kong residents reticent to get latest Covid-19 jab, Moderna survey finds

About 52 per cent of Hong Kong respondents said they were willing to get the updated vaccine, compared with 58 per cent in Singapore.

Hong Kong healthcare and hospitals

Elderly Hongkongers can apply for Covid XBB variant vaccine starting Wednesday

Elderly residents can go to community vaccination stations run by private clinics or designated general outpatient clinics under Hospital Authority.

The first batch of 100,000 doses of the XBB mRNA vaccine manufactured by BioNTech and Pfizer arrived in Hong Kong in late November. Photo: Sam Tsang
Hong Kong healthcare and hospitals

Hong Kong receives first batch of Covid XBB variant vaccines

Vaccination arrangements for the 100,000-jab batch manufactured by US drug firm Pfizer expected to be announced in December.

5
The first batch of Covid XBB variant vaccines has arrived in Hong Kong. Photo: Sam Tsang
Hong Kong healthcare and hospitals

Hong Kong’s private healthcare sector expected to offer RSV vaccine in December

British pharmaceutical company GSK beats Pfizer in race to offer vaccine that can protect elderly against common respiratory infection.

Coronavirus US

Coronavirus: US FDA approves updated Covid-19 vaccines

The FDA decision opens the newest vaccines from Moderna and Pfizer and its partner BioNTech to most Americans even if they have never had a Covid vaccination.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement